CASI Pharma Secures $5M Convertible Note Financing Amid Delisting & Going Concern
CASIF has more than doubled off its 52-week low of $0.05 on light trading volume (0.1× avg).
Summary
CASI Pharmaceuticals, Inc. has raised $5 million through a convertible note, a crucial financing event following its Nasdaq delisting and 'going concern' warning, though it comes with significant dilution and high interest.
Key Events · Financing and Capital Events · CASIF
-
$5 Million Convertible Note Secured
ETP Global III Fund L.P. purchased a $5 million convertible note, representing the fourth tranche of a $20 million financing program.
-
Critical Capital for Distressed Company
This financing is vital for the company, which was delisted from Nasdaq and received a 'going concern' warning on May 15, 2026.
-
Highly Dilutive Terms
The note is convertible at a floor price of $1.00 per share, significantly above the current stock price of $0.14, leading to substantial potential dilution (approximately 24.3% from this tranche alone based on the $1.00 conversion floor).
-
High Interest Rate
The convertible note carries a high annual interest rate of 12%, reflecting the company's financial distress.
Analysis · CASIF · Life Sciences
This filing reveals CASI Pharmaceuticals, Inc. has secured a critical $5 million convertible note financing, which is the fourth tranche of a $20 million program. This capital infusion is essential for the company's survival, especially given its recent delisting from Nasdaq and a 'going concern' warning reported just three days prior. While providing a lifeline for clinical trials and operations, the terms are highly dilutive and expensive, with a 12% interest rate and a conversion price floor of $1.00, significantly above the current market price of $0.14. This transaction highlights the company's urgent need for capital and the challenging terms it must accept.
How filings like this one have moved
In the 30 days to Aug 26, 2026, 43.2% of the 1004 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.10%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CASIF was trading at $0.14 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $0.05 to $3.09. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.